WO2001063285A2 - Verfahren zum nachweis von helicobacter pylori und heilmanii - Google Patents
Verfahren zum nachweis von helicobacter pylori und heilmanii Download PDFInfo
- Publication number
- WO2001063285A2 WO2001063285A2 PCT/EP2001/001639 EP0101639W WO0163285A2 WO 2001063285 A2 WO2001063285 A2 WO 2001063285A2 EP 0101639 W EP0101639 W EP 0101639W WO 0163285 A2 WO0163285 A2 WO 0163285A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pylori
- antibody
- pathogen
- solid phase
- secondary antibody
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 21
- 241000590002 Helicobacter pylori Species 0.000 title claims abstract description 7
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 7
- 239000000427 antigen Substances 0.000 claims abstract description 46
- 102000036639 antigens Human genes 0.000 claims abstract description 46
- 108091007433 antigens Proteins 0.000 claims abstract description 46
- 244000052769 pathogen Species 0.000 claims abstract description 24
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 23
- 239000007790 solid phase Substances 0.000 claims abstract description 20
- 229940096329 human immunoglobulin a Drugs 0.000 claims abstract description 5
- 238000005406 washing Methods 0.000 claims abstract description 4
- 239000007853 buffer solution Substances 0.000 claims abstract 4
- 102000004169 proteins and genes Human genes 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract 2
- 230000028327 secretion Effects 0.000 claims abstract 2
- 210000003296 saliva Anatomy 0.000 claims description 26
- 238000001514 detection method Methods 0.000 claims description 14
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 12
- 238000002560 therapeutic procedure Methods 0.000 claims description 12
- 241000589989 Helicobacter Species 0.000 claims description 8
- 230000008029 eradication Effects 0.000 claims description 8
- 230000003248 secreting effect Effects 0.000 claims description 8
- 229960002685 biotin Drugs 0.000 claims description 6
- 235000020958 biotin Nutrition 0.000 claims description 6
- 239000011616 biotin Substances 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 4
- 210000000214 mouth Anatomy 0.000 claims description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 2
- 241000589876 Campylobacter Species 0.000 claims description 2
- 229910052693 Europium Inorganic materials 0.000 claims description 2
- 102000002464 Galactosidases Human genes 0.000 claims description 2
- 108010093031 Galactosidases Proteins 0.000 claims description 2
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 claims description 2
- 239000010931 gold Substances 0.000 claims description 2
- 229910052737 gold Inorganic materials 0.000 claims description 2
- 235000011330 Armoracia rusticana Nutrition 0.000 claims 1
- 240000003291 Armoracia rusticana Species 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002978 peroxides Chemical class 0.000 claims 1
- 238000012493 sandwich binding assay Methods 0.000 claims 1
- 238000003556 assay Methods 0.000 abstract description 4
- 230000002550 fecal effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 14
- 241000283973 Oryctolagus cuniculus Species 0.000 description 13
- 108060003951 Immunoglobulin Proteins 0.000 description 10
- 102000018358 immunoglobulin Human genes 0.000 description 10
- 238000009739 binding Methods 0.000 description 9
- 239000011534 wash buffer Substances 0.000 description 8
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 208000007882 Gastritis Diseases 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241001591005 Siga Species 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000012723 sample buffer Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- NHZLNPMOSADWGC-UHFFFAOYSA-N 4-amino-N-(2-quinoxalinyl)benzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CN=C(C=CC=C2)C2=N1 NHZLNPMOSADWGC-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 102400001107 Secretory component Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 201000011587 gastric lymphoma Diseases 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000000504 luminescence detection Methods 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 101150063569 slgA gene Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56922—Campylobacter
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
Definitions
- the invention relates to a method for the detection of helicobacter antigens in stool and saliva samples or biopsy materials.
- the human gastric mucosa is often colonized by bacteria of the genera Helicobacter pylori and heilmanii or Ca pylobacter. Infection with these bacteria is likely to occur from person to person, but drinking water and food are not excluded as sources of infection.
- the Helicobacter heilmanii strain is transmitted from pets such as cats, dogs, rabbits, but also from farm animals such as cows. Therefore, people in agriculture and animal care are particularly affected by infections. In Germany, about 10% of schoolchildren, 30% of thirty-year-olds and about 75% of seniors are infected with H. pylori. Around 50% of people worldwide suffer from this infection. H. pylori causes 80% of gastrides, 95% of duodenal ulcers and 70% of ventricular ulcer cases.
- H. pylori gastritis is also considered a precancerous condition for gastric adenocarcinoma and gastric lymphoma.
- WHO World Health Organization
- H. pylori is a carcinogen of the highest cancer risk class. Only a small proportion of H. pylori-infected people develop symptoms. Despite gastritis, many live without any noteworthy symptoms or they attribute the rather unspecific symptoms to other causes.
- Acute H. pylori gastritis is characterized by indefinite pain in the upper and middle abdomen, feeling of pressure and bloating, acid regurgitation, heartburn, as well as nausea and nausea. H.
- H. pylori infection can be detected in almost all patients with type B gastritis. Despite the mostly massive immune response, the infection became chronic. Whether an ulcer develops depends on the patient's immune system and the aggressiveness of the bacteria or the type of bacterial strain. Spontaneous cures are rare. As a rule, an I ylori infection persists throughout life if it is not treated. H. pylori infection can be diagnosed by growing the pathogen from an antrus or corpus biopsy or by histological examination of the tissue. Further diagnostic methods are the CLO test (test for campylobacter like organism) or the urease urea test, the 13 C isotope breath test, the detection of antibodies against H. pylori in serum, the PCR detection of Helicobacter DNA in one Gastric juice or stool sample and the detection of H. pylori antigens in a stool sample.
- CLO test test for campylobacter like organism
- urease urea test the 13 C isotope
- the HpSA test is also unsuitable for controlling eradication therapy, since it only works with abundant amounts of H. pylori antigen in stool.
- the other diagnostic procedures are sometimes very complex, burdensome for the patient or too expensive for routine examinations.
- a disadvantage of the serological methods is that they do not allow therapy control, since the antibody titers remain high for months after the bacteria have eradicated. Control of the therapy is essential, however, since resistance to the antibiotics commonly used for treatment such as clarithromycin, metronidazole, amoxicillin, omeprazole or proton pump inhibitors may be present. Therapy of infections with antibiotics and naturopathic alternatives therefore requires a simple, reliable and sensitive test procedure for H. pylori. This object is achieved by an immunoassay according to claim 1. Preferred embodiments of the invention are described in the subclaims.
- the method according to the invention for the detection of Helicobacter pathogen antigens in a sample is characterized by taking up and suspending a human sample to be examined for the pathogen in a sample buffer; bringing the sample buffer into contact with the pathogen antigen with a solid phase to which at least two different primary antibodies are bound, one of which is capable of binding pathogen antigens and the other of which binds human immunoglobulin; Washing the solid phase of non-specifically bound antigens; Bringing together the solid phase with a secondary antibody that specifically recognizes antigens of the pathogen and determining the amount of bound secondary antibody.
- the amount of bound to the solid phase secondary antibody can be determined, for example ⁇ by a labeling of the antibody.
- the label can be a radioactivity, a luminescent or fluorescent group, a group such as biotin that can be bound by another molecule such as streptavidin, or an enzyme such as peroxidase that catalyzes a detection reaction.
- the amount of secondary antibody bound can also be determined by a further antibody which specifically recognizes the type of secondary antibody and bears one of the abovementioned labels.
- the second primary antibody against human immunoglobulins bound to the solid phase is preferably an antibody which binds human IgA and particularly preferably secretory human IgA which is secreted in the saliva and in the large intestine.
- secretory human IgA here includes human IgA and possibly also the so-called secretory component (MW: 70 kDa), which is "produced by the epithelial cells for transport and 'to protect the IgA before proteoglycans lytic enzymes is particularly preferred.
- a mixture of two primary antibodies which specifically bind IgAl and IgA2 is very particularly preferred.
- the 'bound to the solid phase only primary antibody a polyclonal rabbit anti-J ⁇ .pylori antibody.
- the second primary antibody bound to the solid phase is a goat anti-human s IgA polyclonal antibody tested for cross-reactivities.
- the secondary antibody is a biotin-conjugated rabbit anti-ff. ylori antibody so that the amount of secondary antibody bound can be determined by binding peroxidase-conjugated streptavidin and a color reaction with tetramethylbenzidine.
- the first primary antibody bound to the solid phase is a rabbit anti-i ⁇ . ylori antibody
- the second primary antibody is a rabbit anti-human sIgA antibody
- the secondary antibody is a polyclonal horseradish peroxidase-conjugated goat anti-i ⁇ .pylori antibody.
- other immunoglobulins from horse, cattle, pork, sheep, goat, rabbit, guinea pig, rat, mouse or another animal can also be used. It is particularly important to ensure that the second primary antibody for human immunoglobulin does not bind the secondary antibody against the pathogen antigen in the saliva or stool sample.
- the antibodies can be monoclonal.
- the second primary antibody can be an onoclonal antibody for human IgA2. It is advisable to use several monoclonal antibodies that recognize different epitopes of the pathogen or the human immunoglobulin. For primary monoclonal antibodies, it is advisable to use a mixture of several monoclonal antibodies in order to broaden the specificity of the assay.
- the secondary antibodies are preferably conjugated with one or more markers such as biotin, fluroescein, rhutenium, europium,
- Gold particles alkaline phosphatase, galactosidase or Horseradish peroxidase.
- alkaline phosphatase alkaline phosphatase
- galactosidase galactosidase
- Horseradish peroxidase other suitable marker or detection systems can also be used.
- the ELISA enzyme-linked immunosorbent assay
- the ELISA is used for the qualitative and quantitative determination of H. pylori antigen in stool and saliva samples and bio-specimen material.
- the H.pylori antigen is released from the sample in a first step and bound by a preferably polyclonal anti-i ⁇ .pylori antibody, which is bound in the usual way to a microtiter plate or another solid phase.
- a second primary antibody is also fixed to the solid phase, which recognizes human immunoglobulins and preferably human secretory IgA. Since H.
- pylori antigens have come into contact with the body's own human immune system in a stool or saliva sample, some or all of the H. pylori epitopes have already been bound by human immunoglobulins and are no longer suitable for binding by the first primary antibody against the pathogen accessible.
- the pathogen antigens in the stool or saliva sample and biopsy material even if there is already an immune reaction against them, are concentrated and bound to the solid phase.
- ff.pylori antigens are bound directly and, on the other hand, indirectly via their binding to secreted human immunoglobulin in the saliva or gastrointestinal tract.
- bound F. pylori antigen is then immediately detected by anti-i ⁇ .pylori secondary antibodies. The amount of secondary antibody bound is then quantified using a suitable system.
- the overall specificity of a double antibody assay is essentially determined by the specificity of the secondary antibody.
- the fact that in the first binding step also binds human secretory antibodies with pathogen antigen increases in the case of H. pylori not only the sensitivity, but also the range of the test. It is particularly surprising that, in a significant number of cases, all of the H. pylori immunogenic epitopes are recognized by the existing human immune response. Apparently, the number of immunogenic epitopes is limited in Helicobacter organisms, so that the pathogen epitopes recognized by the human immune system and by the animal primary and secondary antibodies of the double antibody binding assay are often identical.
- Small and masked amounts of H. pylori antigen can be detected by the test principle according to the invention.
- H. pylori The occurrence of Helicobacter pylori in saliva has so far only aroused scientific interest with regard to the putative route of transmission (Namavar F. et al., Eur. J. Clin. Microbiol. Infect. Bis., 1995, 14 (3), pp. 234-7; Shimada T. et al., Lancet, 1994, 343 (8913), pp. 1636-7).
- the lower detection limit for H. pylori is now set so low that an examination of the saliva also allows the diagnosis of an i.pylori infection. It is particularly important for therapy control to examine the patient's saliva for H. pylori antigens. The applicant's investigations showed that H.
- pylori infection nests can be located in the oral cavity - presumably under metal seals and dental prostheses, etc. - which can outlast conventional medicinal eradication therapy and lead to a re-infection of the gastric mucosa after the end of the therapy. Eradication therapy can therefore only be considered complete if H. pylori antigens can no longer be detected in both the stool and saliva samples.
- the sandwich test principle according to the invention with a second primary antibody against human immunoglobulin, in particular against human secretory IgA is not limited to use on a microtiter plate. It can be adapted to fully automated processes that work with coated beads or particles.
- the principle according to the invention with a second primary antibody against secretory human IgA is generally suitable for the diagnosis of pathogens which settle in the mouth or in the gastrointestinal tract and which cause a massive immune reaction.
- the first primary antibody is a pool of polyclonal antibodies against different H. pylori strains. This also applies to the secondary antibody, as this improves the safety of the test.
- FIG. 1 shows a schematic diagram of the immunoassay according to the invention for H. pylori antigen
- Fig. 3 is a graphical representation of the i.pylori antigen concentration in the saliva determined according to the invention before and after an eradication treatment.
- Triton X-100, 0.02% thimerosal, pH 7.4) The stool samples were preferably dosed and homogenized using a
- the saliva sample was diluted 1: 4 or 1: 5 depending on the viscosity in assay buffer and used immediately in the binding assay.
- the assay buffer contains a protease inhibitor such as, for example, 5 mM PMSF.
- protease inhibitors such as Pefabloc SC (Röche Diagnostics) can also be used.
- Coating the microtiter plate The wells of a microtiter plate were coated with polyclonal antibodies against H. pylori antigen and human immunoglobulin-A. For this purpose, 100 ⁇ g of commercially available polyclonal rabbit anti-K. pylori antibodies (DAKO, Hamburg) were added to each well, dissolved in 200 ⁇ l of 60 mM NaCO 3 , pH 9.6, and the plate was incubated at 4 ° C. overnight , The rabbit anti-i ⁇ .pylori antibody solution in the wells was removed and each well was washed with 200 ⁇ l wash buffer (PBS, pH 7.4 with 0.1% Triton X-100).
- PBS pH 7.4 with 0.1% Triton X-100
- Binding assay The determinations were all made in duplicate. 100 ⁇ l standard and sample were pipetted in duplicate into the antibody-coated wells of the microtiter and incubated for one hour while shaking at room temperature. The solutions were removed and the wells of the plate were washed five times with 250 ⁇ l of washing buffer each. After the last wash, the microtiter plate was beaten dry on absorbent paper.
- TMB tetramethylbenzidine
- H. pylori antigens present in the stool sample were completely masked by the body's immune system and therefore could not be bound by the analytical primary antibody against the pathogen. With such a masking of the antigens, a conventional double antibody immunoassay leads to the wrong result that there is no i ⁇ .pylori infection or no longer exists.
- the H. pylori antigens already bound or masked by the human immune system were bound to the solid phase by the second anti-human sIgA primary antibodies (see Table 2, fields shaded in gray). The masking effect was not dependent on the secondary antibody used and not on whether the sample was saliva or stool. Furthermore, the results suggest that the primary bonds of H.
- H. pylori to the solid phase via anti-human slgA antibodies or anti-H. pylori antibodies are mutually exclusive in many cases, that is to say clearly an either-or situation regarding the bond was given.
- the possible primary binding of the H. pylori antigens to the solid phase via binding to human immunoglobulin-A is thus an essential component of the diagnosis according to the invention.
- a saliva sample was taken from 150 patients suspected of H. pylori infection or after eradication therapy and examined for the presence of H. pylori antigens. The analysis was carried out as indicated in Example 1, with the exception that the assay buffer also contained a protease inhibitor.
- the detection limit for Helicobacter antigen in saliva in the test system described above is approximately 2 pg H.pylori antigen per milliliter of assay buffer.
- the result of the series examination is summarized in a bar chart in FIG.
- the bar chart shows that patients with an existing i ⁇ .pylori infection in saliva generally have more than 60 ng / ml H.pylori antigens.
- the examination of the saliva is therefore suitable for the detection of an existing H. pylori infection.
- H.pylori antigen concentrations below 25 ng per ml saliva indicate an unspecific cross-reaction with other pathogens.
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT01919280T ATE259065T1 (de) | 2000-02-14 | 2001-02-14 | Verfahren zum nachweis von helicobacter pylori und heilmanii |
AU2001246433A AU2001246433B2 (en) | 2000-02-14 | 2001-02-14 | Method for Detecting Helicobacter Pylori and Heilmanii in Fecal and Salivery Specimen and Biopsy Material |
DE10190630T DE10190630D2 (de) | 2000-02-14 | 2001-02-14 | Verfahren zum Nachweis von Helicobacter Pylori und Heilmanii in Stuhl- und Speichelproben und Biopsiematerial |
AU4643301A AU4643301A (en) | 2000-02-14 | 2001-02-14 | Method for detecting helicobacter pylori and heilmanii in fecal and salivary specimen and biopsy material |
DE50101435T DE50101435D1 (de) | 2000-02-14 | 2001-02-14 | Verfahren zum nachweis von helicobacter pylori und heilmanii |
EP01919280A EP1257823B1 (de) | 2000-02-14 | 2001-02-14 | Verfahren zum nachweis von helicobacter pylori und heilmanii |
JP2001562198A JP4122419B2 (ja) | 2000-02-14 | 2001-02-14 | 便、唾液試料および生検材料中のヘリコバクターピロリおよびハイルマニの検出方法 |
US11/542,293 US20070087395A1 (en) | 2000-02-14 | 2006-10-03 | Method for detecting pathogenic organisms in fecal and salivary specimens and in biopsy material |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10006432.9 | 2000-02-14 | ||
DE10006432A DE10006432A1 (de) | 2000-02-14 | 2000-02-14 | Verfahren zum Nachweis von Helicobacter pylori in Stuhl- und Speichelproben |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/542,293 Continuation US20070087395A1 (en) | 2000-02-14 | 2006-10-03 | Method for detecting pathogenic organisms in fecal and salivary specimens and in biopsy material |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001063285A2 true WO2001063285A2 (de) | 2001-08-30 |
WO2001063285A3 WO2001063285A3 (de) | 2002-04-11 |
Family
ID=7630808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/001639 WO2001063285A2 (de) | 2000-02-14 | 2001-02-14 | Verfahren zum nachweis von helicobacter pylori und heilmanii |
Country Status (10)
Country | Link |
---|---|
US (2) | US20030148411A1 (de) |
EP (1) | EP1257823B1 (de) |
JP (1) | JP4122419B2 (de) |
AT (1) | ATE259065T1 (de) |
AU (2) | AU2001246433B2 (de) |
CZ (1) | CZ299992B6 (de) |
DE (3) | DE10006432A1 (de) |
DK (1) | DK1257823T3 (de) |
ES (1) | ES2215126T3 (de) |
WO (1) | WO2001063285A2 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003093818A2 (de) * | 2002-05-02 | 2003-11-13 | George Wengler | Verfahren zur vorbehandlung von stuhlproben |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0833756A (ja) * | 1994-07-25 | 1996-02-06 | Asama Seisakusho:Kk | パチンコ機の弾球装置 |
EP1156331B8 (de) * | 2000-05-18 | 2009-08-19 | Meridian Bioscience, Inc. | Immunoassay für H. pylori in Fäkalienproben mit Hilfe von gattungsspezifischen Antikörpern |
ATE475884T1 (de) * | 2006-04-18 | 2010-08-15 | Wellstat Biologics Corp | Detektion von zirkulierenden endothelzellen |
CN102980884A (zh) * | 2012-11-29 | 2013-03-20 | 江苏创生生物技术有限公司 | 胃黏膜样品中幽门螺旋杆菌的化学发光免疫测定法 |
WO2015124707A1 (en) | 2014-02-20 | 2015-08-27 | Immundiagnostik Ag | In vitro diagnostic and prognosis of contrast induced nephropathy (cin) in patients undergoing coronary angiography |
EP3499235A1 (de) | 2017-12-13 | 2019-06-19 | Immundiagnostik AG | Verfahren zur messung von autoantikörpern in körperflüssigkeiten |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0329570A2 (de) * | 1988-02-18 | 1989-08-23 | Martin J. Blaser | Antigene Zusammensetzungen aus Fragmenten von Campylobacter pylori und Verfahren zu ihrer Herstellung und Verwendung |
WO1993022682A1 (en) * | 1992-04-29 | 1993-11-11 | Auspharm International Limited | In vitro test for helicobacter pylori |
WO1998027432A1 (en) * | 1996-12-19 | 1998-06-25 | Chiron Corporation | Helicobacter pylori diagnostics |
WO1999041611A1 (en) * | 1998-02-13 | 1999-08-19 | Consortia Laboratories S.R.L. | Assaying of antibodies directed against one or more antigens of helicobacter pylori in biological liquids by a heterogeneous immunologic method of the reverse type |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0063810B1 (de) * | 1981-04-29 | 1986-03-05 | Ciba-Geigy Ag | Prüfmittel und Ausrüstung für immunologische Analysen |
US5061237A (en) * | 1985-07-02 | 1991-10-29 | Cytomed Medizintechnik Gmbh | Method of purifying whole blood |
US5200051A (en) * | 1988-11-14 | 1993-04-06 | I-Stat Corporation | Wholly microfabricated biosensors and process for the manufacture and use thereof |
US4968604A (en) * | 1989-07-20 | 1990-11-06 | Neorx Corporation | Method and test kit for detection of antibodies |
US5075078A (en) * | 1989-10-05 | 1991-12-24 | Abbott Laboratories | Self-performing immunochromatographic device |
US5646001A (en) * | 1991-03-25 | 1997-07-08 | Immunivest Corporation | Affinity-binding separation and release of one or more selected subset of biological entities from a mixed population thereof |
US5248595A (en) * | 1991-10-08 | 1993-09-28 | Eastman Kodak Company | Wash composition, test kit and method for determination of microorganisms associated with periodontal diseases |
US5807752A (en) * | 1992-09-11 | 1998-09-15 | Boehringer Mannheim Corporation | Assay using an unblocked solid phase with immobilized analyte binding partner |
FI92882C (fi) * | 1992-12-29 | 1995-01-10 | Medix Biochemica Ab Oy | Kertakäyttöinen testiliuska ja menetelmä sen valmistamiseksi |
US5843460A (en) * | 1993-05-19 | 1998-12-01 | Institut Pasteur | Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides |
US5561045A (en) * | 1994-01-04 | 1996-10-01 | Intracel Corporation | Detection reagent, article, and immunoassay method |
US7569341B2 (en) * | 1994-01-31 | 2009-08-04 | Trustees Of Boston University | Nucleic acid directed immobilization arrays and methods of assembly |
WO1995029395A1 (en) * | 1994-04-26 | 1995-11-02 | The Regents Of University Of Michigan | Unitary sandwich enzyme immunoassay cassette, device and method of use |
US5498528A (en) * | 1994-06-10 | 1996-03-12 | King; Wing | Detection of helicobacter pylori |
DE4439452A1 (de) * | 1994-11-04 | 1996-05-09 | Boehringer Mannheim Gmbh | Antikörperklassenspezifisches Entstörungsreagenz |
US5837240A (en) * | 1995-04-28 | 1998-11-17 | Oravax-Merieux Co. | Multimeric, recombinant urease vaccine |
SE9503937D0 (sv) * | 1995-11-07 | 1995-11-07 | Anders Pettersson | Förebyggande av plötslig spädbarnsdöd |
US5716791A (en) * | 1996-05-09 | 1998-02-10 | Meridian Diagnostics, Inc. | Immunoassay for H. pylori in fecal specimens |
US5932430A (en) * | 1996-05-09 | 1999-08-03 | Meridian Diagnostics, Inc. | Immunoassay for H. pylori in fecal specimens |
US6514731B1 (en) * | 1996-05-24 | 2003-02-04 | Chiron Corporation | Methods for the preparation of hepatitis C virus multiple copy epitope fusion antigens |
US5876944A (en) * | 1996-06-10 | 1999-03-02 | Bayer Corporation | Method for amplification of the response signal in a sandwich immunoassay |
US5922845A (en) * | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
US6506384B1 (en) * | 1997-12-31 | 2003-01-14 | New York University | Early detection of mycobacterial disease |
DE69837155T2 (de) * | 1997-09-22 | 2007-06-21 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Verfahren zum nachweiss von antikörpern in einer probe |
DE69812329T2 (de) * | 1997-11-18 | 2004-02-12 | Bio-Rad Laboratories, Inc., Hercules | Multiplex-zufluss-immunotest mit magnetischen teilchen als festphase |
AUPP103497A0 (en) * | 1997-12-19 | 1998-01-15 | Panbio Pty Ltd | Assay apparatus |
DE19758017C2 (de) * | 1997-12-29 | 2000-03-02 | Hanns Ludwig | Verfahren zum Nachweis von Borna-Disease-Virus (BDV)-Infektionen über den Nachweis zirkulierender Immunkomplexe und hierfür verwendbarer diagnostischer Kit |
US7297312B2 (en) * | 1998-03-16 | 2007-11-20 | University Of Cincinnati | Simultaneous multianalyte electrochemical assay based on spatial resolution |
US6303081B1 (en) * | 1998-03-30 | 2001-10-16 | Orasure Technologies, Inc. | Device for collection and assay of oral fluids |
US6221579B1 (en) * | 1998-12-11 | 2001-04-24 | Kimberly-Clark Worldwide, Inc. | Patterned binding of functionalized microspheres for optical diffraction-based biosensors |
AU4701200A (en) * | 1999-05-07 | 2000-11-21 | Quantum Dot Corporation | A method of detecting an analyte using semiconductor nanocrystals |
US6383740B2 (en) * | 1999-07-30 | 2002-05-07 | Bioergonomics, Inc. | Methods for simultaneously detecting both members of a binding pair |
US6727073B1 (en) * | 1999-11-19 | 2004-04-27 | Binax, Inc. | Method for detecting enteric disease |
TWI237695B (en) * | 1999-12-14 | 2005-08-11 | Joy Biomedical Corp | Helicobacter pylori antigens in blood |
US6316205B1 (en) * | 2000-01-28 | 2001-11-13 | Genelabs Diagnostics Pte Ltd. | Assay devices and methods of analyte detection |
US20020004246A1 (en) * | 2000-02-07 | 2002-01-10 | Daniels Robert H. | Immunochromatographic methods for detecting an analyte in a sample which employ semiconductor nanocrystals as detectable labels |
US20010051351A1 (en) * | 2000-03-27 | 2001-12-13 | Racis Stanley Paul | Antigen-specific immune complex-based enzyme-linked immunosorbent assay |
US6699722B2 (en) * | 2000-04-14 | 2004-03-02 | A-Fem Medical Corporation | Positive detection lateral-flow apparatus and method for small and large analytes |
US6528325B1 (en) * | 2000-10-13 | 2003-03-04 | Dexall Biomedical Labs, Inc. | Method for the visual detection of specific antibodies in human serum by the use of lateral flow assays |
-
2000
- 2000-02-14 DE DE10006432A patent/DE10006432A1/de not_active Withdrawn
-
2001
- 2001-02-14 CZ CZ20023063A patent/CZ299992B6/cs not_active IP Right Cessation
- 2001-02-14 JP JP2001562198A patent/JP4122419B2/ja not_active Expired - Fee Related
- 2001-02-14 US US10/203,679 patent/US20030148411A1/en not_active Abandoned
- 2001-02-14 ES ES01919280T patent/ES2215126T3/es not_active Expired - Lifetime
- 2001-02-14 WO PCT/EP2001/001639 patent/WO2001063285A2/de active IP Right Grant
- 2001-02-14 AU AU2001246433A patent/AU2001246433B2/en not_active Ceased
- 2001-02-14 DK DK01919280T patent/DK1257823T3/da active
- 2001-02-14 AU AU4643301A patent/AU4643301A/xx active Pending
- 2001-02-14 DE DE50101435T patent/DE50101435D1/de not_active Expired - Lifetime
- 2001-02-14 DE DE10190630T patent/DE10190630D2/de not_active Ceased
- 2001-02-14 AT AT01919280T patent/ATE259065T1/de active
- 2001-02-14 EP EP01919280A patent/EP1257823B1/de not_active Expired - Lifetime
-
2006
- 2006-10-03 US US11/542,293 patent/US20070087395A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0329570A2 (de) * | 1988-02-18 | 1989-08-23 | Martin J. Blaser | Antigene Zusammensetzungen aus Fragmenten von Campylobacter pylori und Verfahren zu ihrer Herstellung und Verwendung |
WO1993022682A1 (en) * | 1992-04-29 | 1993-11-11 | Auspharm International Limited | In vitro test for helicobacter pylori |
WO1998027432A1 (en) * | 1996-12-19 | 1998-06-25 | Chiron Corporation | Helicobacter pylori diagnostics |
WO1999041611A1 (en) * | 1998-02-13 | 1999-08-19 | Consortia Laboratories S.R.L. | Assaying of antibodies directed against one or more antigens of helicobacter pylori in biological liquids by a heterogeneous immunologic method of the reverse type |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003093818A2 (de) * | 2002-05-02 | 2003-11-13 | George Wengler | Verfahren zur vorbehandlung von stuhlproben |
WO2003093818A3 (de) * | 2002-05-02 | 2004-02-26 | George Wengler | Verfahren zur vorbehandlung von stuhlproben |
Also Published As
Publication number | Publication date |
---|---|
CZ20023063A3 (cs) | 2003-01-15 |
JP4122419B2 (ja) | 2008-07-23 |
ATE259065T1 (de) | 2004-02-15 |
DE10006432A1 (de) | 2001-08-16 |
US20070087395A1 (en) | 2007-04-19 |
WO2001063285A3 (de) | 2002-04-11 |
ES2215126T3 (es) | 2004-10-01 |
US20030148411A1 (en) | 2003-08-07 |
DE50101435D1 (de) | 2004-03-11 |
EP1257823A2 (de) | 2002-11-20 |
JP2003526779A (ja) | 2003-09-09 |
DE10190630D2 (de) | 2002-12-05 |
CZ299992B6 (cs) | 2009-01-14 |
AU2001246433B2 (en) | 2005-03-24 |
AU4643301A (en) | 2001-09-03 |
EP1257823B1 (de) | 2004-02-04 |
DK1257823T3 (da) | 2004-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69709434T3 (de) | Immunoassay für H. pylori in Fäkalienproben | |
Proudman et al. | Correlation of antigen specific IgG and IgG (T) responses with Anoplocephala perfoliata infection intensity in the horse | |
Alkout et al. | Isolation of a cell surface component of Helicobacter pylori that binds H type 2, Lewis (a), and Lewis (b) antigens | |
Deplazes et al. | An enzyme-linked immunosorbent assay for diagnostic detection of Taenia saginata copro-antigens in humans | |
US20040115624A1 (en) | Method for simultaneous detection of multiple microbial antigens in biological specimens from mastitic animals | |
WO2001027612A2 (de) | Immunchromatographischer schnelltest zum nachweis von säure-resistenten mikroorganismen im stuhl | |
WO2000026671A1 (de) | Nachweis von säure-resistenten mikroorganismen im stuhl | |
DE202005020939U1 (de) | Kit zur Messung der Aktivierung neutrophiler Zellen | |
KR100868560B1 (ko) | 렙토스피라증 진단 키트 | |
US20070087395A1 (en) | Method for detecting pathogenic organisms in fecal and salivary specimens and in biopsy material | |
DE69933707T2 (de) | Serum amyloid a als marker für entzündungsreaktion, milchqualität und die anwesenheit von kolostrum in milch | |
EP1151135A1 (de) | Schneller immuntest für kariogene bakterien | |
Kania et al. | Anoplocephala perfoliata coproantigen detection: a preliminary study | |
EP1747025B1 (de) | Verfahren zur diagnose von infektionskrankheiten | |
DE69628713T2 (de) | Marker und Reagenz für Diabetes mellitus und Diabetes-mellitus-Komplikationen | |
DE10101792B4 (de) | Verfahren zum Nachweis von Pankreaskarzinom oder chronischer Pankreatitis und Verwendung von Antikörpern | |
DE60010301T2 (de) | Versuchsanordnung zur diagnose von mastitis durch nachweis von haptoglobin | |
Allan et al. | Partial characterization and time course analysis of Hymenolepis diminuta coproantigens | |
EP1499896B1 (de) | Verfaren zur diagnose von neoplasmen | |
DE19758017C2 (de) | Verfahren zum Nachweis von Borna-Disease-Virus (BDV)-Infektionen über den Nachweis zirkulierender Immunkomplexe und hierfür verwendbarer diagnostischer Kit | |
US20180196042A1 (en) | Homogeneous competitive lateral flow assay | |
WO2002050546A2 (de) | Bestimmung des cytosolishce nadp-abhangige malat decarboxylase-isoenzymes | |
DE19548375A1 (de) | Immunologische Bestimmungsmethode | |
EP0565903B1 (de) | Verfahren zur immunologischen Bestimmung eines oder mehrerer Analyten | |
DE19523553A1 (de) | Helicobacter pylori Carboanhydrase-artiges Protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001919280 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 562198 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001246433 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2002-3063 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 2001919280 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV2002-3063 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10203679 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8607 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001919280 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001246433 Country of ref document: AU |